Neuroendocrine tumors of unknown primary site: Gold dust or misdiagnosed neoplasms?

Tumori

Volumn 97, Issue 5, 2011, Pages 564-567

  Catena, Laura ^a,c   Bichisao, Ettore ^b   Milione, Massimo ^a   Valente, Monica ^a   Platania, Marco ^a   Pusceddu, Sara ^a   Ducceschi, Monika ^a   Zilembo, Nicoletta ^a   Formisano, Barbara ^a   Bajetta, Emilio ^a,c  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b Fondazione Giacinto Facchetti per lo Studio e la Cura dei Tumori ONLUS   (Italy)

^c Istituto di Oncologia   (Italy)

Author keywords

Neuroendocrine tumors; Octreoscan; Rare tumors; Unknown primary site

Indexed keywords

ANTINEOPLASTIC AGENT; INTERFERON; PENTETREOTIDE; SOMATOSTATIN DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER INCIDENCE; CANCER MORTALITY; CANCER OF UNKNOWN PRIMARY SITE; CANCER SURGERY; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ERROR; FEMALE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROENDOCRINE TUMOR; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; SURVIVAL TIME;

EID: 83055172229     PISSN: 03008916     EISSN: 20382529     Source Type: Journal    
DOI: 10.1177/030089161109700504     Document Type: Article

References (9)

1. Levi F, Te VC, Erler G, Randimbison L, La Vecchia C: Epidemiology of unknown primary tumours. Eur J Cancer, 38: 1810-1812, 2202.
2. Van de Wouw AJ, Janssen-Heijnen MLG, Coeberg JWW, Hillen HFP: Epidemiology of unknown primary tumors: incidence and population-based survival of 1285 patients in Southern Netherlands, 1984-1992. Eur J Cancer, 38: 400-413, 2202.
3. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A, Evans DB: One hundred years after "carcinoids": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol, 26: 3063-3072, 2008.
4. Spigel DR, Hainsworth JD, Greco FA: Neuroendocrine carcinoma of unknown primary site. Semin Oncol, 36: 52-59, 2009.
5. Solcia E, Kloppel G, Sobin LH, Capella C, Heitz PU: Histologic typing of endocrine tumors. In: WHO International Histological Classification of Tumors, pp 1-156, Springer- Verlag, Heidelberg, 2000.
6. Bajetta E, Catena L, Procopio G, Bichisao E, Ferrari L, Della Torre S, De Dosso S, Iacobelli S, Buzzoni R, Mariani L, Rosai J: Is the newWHO classification of neuroendocrine tumors useful for selecting an appropriate treatment? Ann Oncol, 16: 1374-1380, 2005. (Pubitemid 41158484)
7. Bajetta E, Ferrari L, Procopio G, Catena L, Ferrario E, Martinetti A, Di Bartolomeo M, Buzzoni R, Celio L, Vitali M, Beretta E, Seregni E, Bombardieri E: Efficacy of chemotherapy combinations for the treatment of metastatic neuroendocrine tumors. Ann Oncol, 13: 614-621, 2002. (Pubitemid 34461146)
8. Bajetta E, Zilembo N, Di Bartolomeo M, Di Leo A, Pilotti S, Bochicchio AM, Castellani R, Buzzoni R, Celio L, Dogliotti L: Treatment of metastatic carcinoid and other neuroendocrine tumors with recombinant interferon alpha-2a. Cancer, 72: 3099-3100, 1993.
9. Kirshbom PM, Kherani AR, Onaitis MW, Feldman JM, Tyler DS: Carcinoids of unknown origin: comparative analysis with foregut, midgut and hindgut carcinoids. Surgery, 124: 1063-1070, 1998. (Pubitemid 28555194)